Cited by 187Atrial Fibrillation Management and OutcomesCardiac electrophysiology and arrhythmiasCardiac Arrhythmias and Treatments

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) Trial

Goette, Andreas, Schön, Norbert, Kirchhof, Paulus, Breithardt, Günter, Fetsch, Thomas, Häusler, Karl Georg, Klein, Helmut U., Steinbeck, Gerhard, Wegscheider, Karl, Meinertz, Thomas·2012·Circulation Arrhythmia and Electrophysiology

DOI 10.1161/circep.111.965178

Open this paper in CoChat — free account

Abstract

BACKGROUND: Unlike antiarrhythmic drugs, the safety and beneficial effects of angiotensin II receptor blockade (ARB) in patients with structural heart disease is well established. The clinical efficacy of ARBs to prevent atrial fibrillation (AF) so far only has been shown in patients with structural heart disease. Here, we report the primary outcome of the Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) trial, which investigated the effect of olmesartan medoxomil compared with placebo on AF burden in patients with paroxysmal AF without structural heart disease. METHODS AND RESULTS: The ANTIPAF trial was a prospective, randomized, placebo-controlled, multicenter trial analyzing the AF burden (percentage of days with documented episodes of paroxysmal AF) during a 12-month follow-up as the primary study end point. Four hundred thirty patients with documented paroxysmal AF without structural heart disease were randomized to placebo or 40 mg olmesartan per day. Concomitant therapy with ARBs, angiotensin-converting enzyme inhibitors, and antiarrhythmic drugs was prohibited. Patients were followed using daily transtelephonic ECG (tele-ECG) recordings independent of symptoms. The intention-to-treat population of the trial encompassed 425 patients (placebo group, n=211; olmesartan group, n=214). A total of 87 818 tele-ECGs were analyzed in these patients during follow-up (placebo group, 44 888 ECGs; olmesartan group, 42 930 ECGs). Thus, a mean of 207 tele-ECGs were recorded per patient. The primary end point (AF burden) was not different between the 2 groups (P=0.770). Secondary outcome parameters, including quality of life, also were not different. In particular, time to first AF recurrence, time to persistent AF, and number of hospitalizations were not different between the 2 groups. The time to prescription of recovery medication (amiodarone) was the only parameter showing an intergroup difference, with earlier prescription of amiodarone in the placebo group (P=0.022). CONCLUSIONS: One year of ARB therapy per se does not reduce the number of AF episodes in patients with documented paroxysmal AF without structural heart disease. Clinical Trial Registration- URL: http://www.clinicaltrials.gov. Unique identifier: NCT00098137.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1161/circep.111.965178

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Prevalence of Diagnosed Atrial Fibrillation in Adults: National Implications for Rhythm Management and Stroke Prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study
Go, A. S., Hylek, E. M., Phillips, K. A., Chang, Y., Henault, L. E., Selby, J. V., & Singer, D. E. (2001) · JAMA · doi:10.1001/jama.285.18.2370 · Cited by 6,205
Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Kirchhof, P. F., Lip, G. Y. H., Schotten, U., Savelieva, I., Ernst, S., Gelder, I. C. V., Al‐Attar, N., Hindricks, G., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq278 · Cited by 5,954
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.177292 · Cited by 2,805
Epidemiologic Features of Chronic Atrial Fibrillation
Kannel, W. B., Abbott, R. D., Savage, D. D., & McNamara, P. M. (1982) · New England Journal of Medicine · doi:10.1056/nejm198204293061703 · Cited by 2,304
Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Kirchhof, P. F., Lip, G. Y. H., Schotten, U., Savelieva, I., Ernst, S., Gelder, I. C. V., Al‐Attar, N., Hindricks, G., et al. (2010) · EP Europace · doi:10.1093/europace/euq350 · Cited by 1,764
New ideas about atrial fibrillation 50 years on
Nattel, S. (2002) · Nature · doi:10.1038/415219a · Cited by 1,481
Promotion of Atrial Fibrillation by Heart Failure in Dogs
Li, D., Fareh, S., Leung, T. K., & Nattel, S. (1999) · Circulation · doi:10.1161/01.cir.100.1.87 · Cited by 1,343
Relationships Between Sinus Rhythm, Treatment, and Survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study
The AFFIRM Investigators (2004) · Circulation · doi:10.1161/01.cir.0000121736.16643.11 · Cited by 1,202
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol
Wachtell, K., Lehto, M., Gerdts, E., Olsen, M. H., Hornestam, B., Dahlöf, B., Ibsen, H., Julius, S., Kjeldsen, S. E., Lindholm, L. H., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.10.068 · Cited by 826

Show all 34 references

Research works printed but not linked: 1

Maurer W, Hothorn LA, Lehmacher W Multiple comparisons in drug clinical trials and preclinical assays: a priori ordered hypotheses. In: , Vollmar J , ed. Biometrie in der Chemisch-Pharmazeutischen Industrie, Band 6. Stuttgart, Germany: Fischer; 1995: 13–18.

Sorted by citations

Items 101–186 of 186

Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial
Jiang, C., Zhao, Z., Yang, Z., Wang, Y., Yang, X., Xu, H., Guo, H., Wang, C., He, L., Xia, S., et al. (2025) · Circulation · doi:10.1161/circulationaha.125.077447 · Cited by 17
Early management of atrial fibrillation: from imaging to drugs to ablation
Shah, A. J., Liu, X., Jadidi, A., & Haı̈ssaguerre, M. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.49 · Cited by 14
Biomarkers of Atrial Fibrillation: Which One Is a True Marker?
Ardhianto, P., & Yuniadi, Y. (2019) · Cardiology Research and Practice · doi:10.1155/2019/8302326 · Cited by 14
Atrial fibrillation in heart failure patients: An update on renin–angiotensin–aldosterone system pathway blockade as a therapeutic and prevention target
Koniari, I. C., Artopoulou, E., Mplani, V., Mulita, F., Alexopoulou, E., Chourdakis, E., Abo-Elseoud, M., Tsigkas, G., Panagiotopoulos, I. A., Kounis, N. G., et al. (2022) · Cardiology Journal · doi:10.5603/cj.a2022.0061 · Cited by 14
Predictors of discordance between physicians' and patients' appraisals of health-related quality of life in atrial fibrillation patients: Findings from the Angiotensin II Antagonist in Paroxysmal Atrial Fibrillation Trial
Rothe, A. V. E., Bielitzer, M., Meinertz, T., Limbourg, T., Ladwig, K., & Goette, A. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.05.020 · Cited by 14
Tailored treatment strategies: a new approach for modern management of atrial fibrillation
Gelder, I. C. V., Hobbelt, A. H., Marcos, E. G., Schotten, U., Cappato, R., Lewalter, T., Schwieler, J. H., Rienstra, M., & Boriani, G. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12489 · Cited by 14
Atrial Fibrillation and Hypertension: “Quo Vadis”
Kwon, Y., Walker, M., Patel, P., Kwon, O., Koene, R. J., & Duprez, D. A. (2022) · Current Hypertension Reviews · doi:10.2174/1573402118666220112122403 · Cited by 15
Incidence and progression of atrial fibrillation in patients with and without heart failure using mineralocorticoid receptor antagonists: a meta-analysis
Rodrigues, T. S., Quarto, L. J. G., Nogueira, S. C., Koshy, A. N., Mahajan, R., Sanders, P., Ekinci, E. I., Burrell, L. M., Farouque, O., & Lim, H. S. (2024) · Clinical Research in Cardiology · doi:10.1007/s00392-023-02349-3 · Cited by 13
Summary of the Clinical Studies Reported in the European Society of Cardiology Congress 2010 (August 28-September 1, 2010, Stockholm, Sweden)
Bayés‐Genís, A., y, P. A., de Isla, L. P., Sanchís, J. M., & Heras, M. (2010) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(10)70254-1 · Cited by 13
Of hammers and screws: renin-angiotensin-aldosterone system inhibition to prevent atrial fibrillation in patients with hypertension
Kirchhof, P. F., & Fabritz, L. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu068 · Cited by 12
Primary prevention of atrial fibrillation with beta-blockers in patients with end-stage renal disease undergoing dialysis
Lin, T., Chiang, J., Liao, M., Tsai, C., Hwang, J., Chiang, F., Lin, J.-L., & Lin, L. (2015) · Scientific Reports · doi:10.1038/srep17731 · Cited by 12
Recent Clinical Trials in Atrial Fibrillation in Hypertensive Patients
Manolis, A. J., Kallistratos, M. S., & Poulimenos, L. E. (2012) · Current Hypertension Reports · doi:10.1007/s11906-012-0268-5 · Cited by 12
Effect of carvedilol on atrial remodeling in canine model of atrial fibrillation.
Kishihara, J., Niwano, S., Niwano, H., et al. (2014) · PubMed · doi:10.3978/j.issn.2223-3652.2014.02.03 · Cited by 12
The role of angiotensin receptor blockers in the prevention of cardiovascular and renal disease: time for reassessment?
Fuchs, F. D. (2012) · BMJ Evidence-Based Medicine · doi:10.1136/eb-2012-100851 · Cited by 12
Antiarrhythmic Drug Therapy for Atrial Fibrillation
Sardar, M. R., Saeed, W., & Kowey, P. R. (2014) · Cardiology Clinics · doi:10.1016/j.ccl.2014.07.012 · Cited by 11
A porcine model of early atrial fibrillation using a custom-built, radio transmission-controlled pacemaker
Schwarzl, M., Alogna, A., Zweiker, D., Verderber, J., Huber, S., Manninger, M., Scherr, D., Antoons, G., Pieske, B. M., Post, H., et al. (2015) · Journal of Electrocardiology · doi:10.1016/j.jelectrocard.2015.12.012 · Cited by 12
Study on the Effect of Irbesartan on Atrial Fibrillation Recurrence in Kumamoto: Atrial Fibrillation Suppression Trial (SILK study)
Yamabe, H., Kaikita, K., Matsumura, T., Iwasa, A., Koyama, J., Uemura, T., Morikami, Y., Tsunoda, R., Morihisa, K., Fujimoto, K., et al. (2017) · Journal of Cardiology · doi:10.1016/j.jjcc.2017.07.010 · Cited by 12
Atrial fibrillation in severe aortic valve stenosis — Association with left ventricular left atrial remodeling
Dahl, J. S., Brandes, A., Videbæk, L. M., Poulsen, M. K., Carter‐Storch, R., Christensen, N. L., Banke, A., Pellikka, P. A., & Møller, J. E. (2014) · IJC Heart & Vessels · doi:10.1016/j.ijchv.2014.06.006 · Cited by 12
Rivaroxaban versus warfarin in Japanese patients with non-valvular atrial fibrillation in relation to hypertension: a subgroup analysis of the J-ROCKET AF trial
on behalf of the J-ROCKET AF Study Investigators, Matsumoto, M., Hori, M., Tanahashi, N., Momomura, S., Uchiyama, S., Goto, S., Izumi, T., Koretsune, Y., Kajikawa, M., et al. (2014) · Hypertension Research · doi:10.1038/hr.2014.1 · Cited by 11
Angiotensin receptor blockers for prevention of cardiovascular disease: where does the evidence stand?
Fuchs, F. D., & DiNicolantonio, J. J. (2015) · Open Heart · doi:10.1136/openhrt-2014-000236 · Cited by 11
Estimated atrial fibrillation burden on early rhythm-control and cardiovascular events in the EAST-AFNET 4 trial
Zeemering, S., Borof, K., Schotten, U., Obergassel, J., Camm, A. J., Crijns, H. J. G. M., Eckardt, L., Fabritz, L., Goette, A., Habibi, Z., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103457 · Cited by 13
“An identical method was used to estimate AF burden in the ANTIPAF-AFNET 2 trial, 23 obtaining similar AF burden estimates in paroxysmal AF (10”
Upstream therapeutic strategies of Valsartan and Fluvastatin on Hypertensive patients with non-permanent Atrial Fibrillation (VF-HT-AF): study protocol for a randomized controlled trial
Qi, W., Liu, T., Xu, G., Li, L., Liang, Y., Ye, L., & Li, G. (2015) · Trials · doi:10.1186/s13063-015-0836-5 · Cited by 10
Age and CHADS2 Score Predict the Effectiveness of Renin-Angiotensin System Blockers on Primary Prevention of Atrial Fibrillation
Hung, C.-Y., Hsieh, Y., Li, C.-H., Huang, J., Lin, C., & Wu, T. (2015) · Scientific Reports · doi:10.1038/srep11442 · Cited by 10
Does rhythm matter in acute heart failure? An insight from the British Society for Heart Failure National Audit
Anderson, S. G., Shoaib, A., Myint, P. K., Cleland, J. G. F., Hardman, S. M. C., McDonagh, T. A., Dargie, H., Keavney, B. D., Garratt, C. J., & Mamas, M. A. (2019) · Clinical Research in Cardiology · doi:10.1007/s00392-019-01463-5 · Cited by 10
Updates in the management of atrial fibrillation: Emerging therapies and treatment
Al-Ezzi, S. M. S., Bista, I., Al-Ezzi, M. M., Prajjwal, P., Al-Ezzi, S. M. S., Pattani, H. H., Amiri, B., & Marsool, M. D. M. (2023) · Disease-a-Month · doi:10.1016/j.disamonth.2023.101633 · Cited by 9
Atrial Fibrillation and the Renin-Angiotensin-Aldosterone System
Perlini, S., Belluzzi, F., Salinaro, F., & Musc, F. (2013) · InTech eBooks · doi:10.5772/53917 · Cited by 9
Upstream Therapy for Atrial Fibrillation in Heart Failure
Goette, A. (2013) · Heart Failure Clinics · doi:10.1016/j.hfc.2013.07.010 · Cited by 8
Risk factor modification for the primary and secondary prevention of atrial fibrillation. Part 1
Mujović, N. M., Marinković, M. M., Mihajlovic, M., Mujović, N., & Potpara, T. (2020) · Kardiologia Polska · doi:10.33963/kp.15221 · Cited by 9
The year in cardiology 2014: arrhythmias and device therapy
Heidbüchel, H., & Hindricks, G. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu486 · Cited by 7
Modifiable Risk Factors and Atrial Fibrillation: the Quest for a Personalized Approach
Matei, L.-L., Silişte, C., & Vinereanu, D. (2021) · MAEDICA – a Journal of Clinical Medicine · doi:10.26574/maedica.2020.16.1.88 · Cited by 8
The European Network for Translational Research in Atrial Fibrillation (EUTRAF): objectives and initial results
Schotten, U., Hatem, S. N., Ravens, U., Jaı̈s, P., Müller, F.-U., Goette, A., Rohr, S., Antoons, G., Pieske, B. M., Scherr, D., et al. (2015) · EP Europace · doi:10.1093/europace/euv252 · Cited by 7
Blood pressure targets, medication considerations and special concerns in elderly hypertension: Focus on atherosclerotic cardiovascular diseases, atrial fibrillation, heart failure, and aortic stenosis
Hsu, R.-Y., Lo, H.-Y., Chen, C.-H., Wu, Y.-J., Chan, D., Wu, C., Wang, T., Kao, H., Sun, W., Lin, Y., et al. (2025) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2025.05.007 · Cited by 8
Atrial Fibrillation and Heart Failure With Reduced Ejection Fraction
Boehmer, A. A., Ehrlich, J. R., & Nattel, S. (2025) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2025.09.014 · Cited by 10
Long-term treatment of spontaneously hypertensive rats with losartan and molecular basis of modulating Ito of ventricular myocytes
Zhang, H., Wu, S., Huang, C. Y., et al. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2001 · Cited by 6
Wytyczne ESH/ESC dotyczące postępowania w nadciśnieniu tętniczym w 2013 roku
Suplement, K. P. (2013) · Kardiologia Polska · doi:10.5603/kp.2013.0177 · Cited by 7
Class I Antiarrhythmic Drugs: Na+ Channel Blockers
Shenasa, M., Shenasa, M.-A., & Smith, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-34893-9_2 · Cited by 6
Beneficial effects of losartan for prevention of paroxysmal atrial fibrillation in patients with sick sinus syndrome: analysis with memory function of pacemaker
Takii, E., Inage, T., Yoshida, T., Ohe, M., Gondo, T., Haraguchi, G., Ito, S., Kumanomido, J., Imaizumi, T., & Fukuomoto, Y. (2015) · Heart and Vessels · doi:10.1007/s00380-015-0627-7 · Cited by 6
Effect of antihypertensive agents on the risk of new-onset and recurrent atrial fibrillation: a Bayesian network meta-analysis of randomized controlled trials
Gewehr, D. M., Carvalho, P. E. P., Martignoni, F., Nogueira, A., Gomes, C. P., Navalha, D. D. P., Pirez, J., Melo, L., de Mesquita, Y. L. L., Braga, M. A. P., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf335 · Cited by 7
Preventive effect of renin-angiotensin system inhibitors on new-onset atrial fibrillation in hypertensive patients: a propensity score matching analysis
Horio, T., Akiyama, M., Iwashima, Y., Yoshihara, F., Nakamura, S., Tokudome, T., Okutsu, M., Tanaka, H., Komatsubara, I., Okimoto, N., et al. (2016) · Journal of Human Hypertension · doi:10.1038/jhh.2016.95 · Cited by 5
Olmesartan Reduces New-onset Atrial Fibrillation and Atrial Fibrillation Burden after Dual-chamber Pacemaker Implantation in Atrioventricular Block Patients
Zhang, H., Pan, C., Zhang, J., Zhu, L., Huang, K., Zhong, Y., & Hu, Z. (2016) · Chinese Medical Journal · doi:10.4103/0366-6999.189924 · Cited by 5
Blood Pressure Control versus Atrial Fibrillation Management in Stroke Prevention
Savoia, C., Sada, L., & Volpe, M. (2015) · Current Hypertension Reports · doi:10.1007/s11906-015-0553-1 · Cited by 5
Renin-Angiotensin System and AtrialFibrillation:Understanding the Connection.
Disertori, M., & Quintarelli, S. (2011) · Europe PMC (PubMed Central) · doi:10.4022/jafib.398 · Cited by 5
The vanishing story of angiotensin II receptor blockers in the treatment of atrial fibrillation
Goette, A. (2011) · EP Europace · doi:10.1093/europace/eur045 · Cited by 5
Effect of Perindopril on Atrial Fibrillation Recurrence and Burden: Results of the Canadian Trial of Atrial Fibrillation (CTAF)-2
Rivard, L., Samuel, M., Fortier, A., Guertin, M., Khairy, P., Roy, D., Talajic, M. R., & Tardif, J. (2021) · CJC Open · doi:10.1016/j.cjco.2021.04.014 · Cited by 4
Atrial Remodelling : Role in Atrial Fibrillation Ablation.
Grubitzsch, H., & Haverkamp, W. (2012) · Europe PMC (PubMed Central) · doi:10.4022/jafib.691 · Cited by 4
Data mining experiments on the Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF-AFNET 2) trial: ‘exposing the invisible’
Okutucu, S., Katircioglu-Öztürk, D., Oto, E., Güvenir, H. A., Karaağaoğlu, E., Oto, A., Meinertz, T., & Goette, A. (2016) · EP Europace · doi:10.1093/europace/euw084 · Cited by 4
Gq-Mediated Arrhythmogenic Signaling Promotes Atrial Fibrillation
Hohendanner, F., Prabhu, A., Wilck, N., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11020526 · Cited by 3
Omentin-1 attenuates atrial fibrillation via Src/PI3K/Akt signaling-mediated anti-fibrotic effects in cardiac fibroblasts
Li, T.-L., Zhu, N.-N., Zhao, M.-X., et al. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177588 · Cited by 3
Selective atrial profibrotic signalling in mice and man
Fabritz, L., & Kirchhof, P. F. (2013) · Cardiovascular Research · doi:10.1093/cvr/cvt188 · Cited by 3
The RACE-3 is on: double-locking sinus rhythm by upstream and downstream therapy
Pavlović, D., Kirchhof, P. F., & Fabritz, L. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy018 · Cited by 3
Left ventricular fibrosis in atrial fibrillation and heart failure with reduced ejection fraction: A comprehensive review of mechanisms, clinical implications, and therapeutic perspectives
Cho, K. K., Segan, L. A., Anthony, C., et al. (2026) · Heart Rhythm · doi:10.1016/j.hrthm.2026.06.017 · Cited by 2
Prevention of Atrial Fibrillation After Atrial Flutter Ablation With Ramipril (from the PREFACE Study)
Guichard, J.-B., Anselme, F., Defaye, P., Mansourati, J., Pavin, D., Pasquié, J., Saludas, Y., Barthélemy, J., Roche, F., Laporte, S., et al. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.09.010 · Cited by 2
Losartan inhibits hyposmotic-induced increase of IKs current and shortening of action potential duration in guinea pig atrial myocytes
Gao, J. (2019) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2019.75332 · Cited by 2
Novel Therapeutic Targets in the Management of Atrial Fibrillation
Maan, A., MANSOUR, M. C., McManus, D. D., Patel, V. V., Cheng, A., Ruskin, J. N., & Heist, E. K. (2014) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-014-0085-0 · Cited by 2
Upstream-Therapie bei Vorhofflimmern
Goette, A., Hammwöhner, M., & Bukowska, A. (2014) · Herzschrittmachertherapie + Elektrophysiologie · doi:10.1007/s00399-014-0303-0 · Cited by 2
2018 Korean Heart Rhythm Society Guidelines for Detection and Management of Risk Factors and Concomitant Cardiovascular Diseases in Korean Patients with Atrial Fibrillation
Lee, S.-R., Lee, Y.-S., Lim, W., Kim, T.-H., Cha, M., Lee, J., Baek, Y., Lim, H., Joung, B., Kim, J., et al. (2018) · Korean Journal of Medicine · doi:10.3904/kjm.2018.93.4.324 · Cited by 2
PPAR-γ activation limits angiotensin II-mediated atrial remodeling: One drug fits all AF patients?
Lendeckel, U., Wolke, C., & Goette, A. (2013) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2013.12.001 · Cited by 1
12 Jahre AFNET. Vom Forschungsnetzwerk zur Academic Research Organisation
Kirchhof, P. F., Goette, A., Näbauer, M., & Schotten, U. (2016) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-016-2323-x · Cited by 1
Selecting Optimum Antihypertensive Therapy
Papademetriou, V., & Doumas, M. N. (2016) · Springer eBooks · doi:10.1007/978-3-319-39599-9_15 · Cited by 1
Prevention and Treatment
Fuchs, F. D. (2017) · Springer eBooks · doi:10.1007/978-3-319-63272-8_4 · Cited by 1
Atrial Fibrillation. Modern Epidemiologic and Therapeutic Aspects
Poulimenos, L. E., Kallistratos, M. S., & Manolis, A. J. (2012) · Springer eBooks · doi:10.1007/978-88-470-2601-8_32 · Cited by 1
РЕКОМЕнДАЦИИ ПО ЛЕЧЕнИЮ АРТЕРИАЛЬнОЙ ГИПЕРТОнИИ. ESH/ESC 2013 Рабочая группа по лечению артериальной гипертонии европейского Общества Гипертонии (European society of hypertension, Esh) и европейского Общества кардиологов (European society of Cardiology, EsC).
Mancia, G., & Fagard, R. H. (2013) · Cited by 1
Clinical Trials for Atrial Fibrillation—What Do We Know?
Chew, D. S., & Wilton, S. B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809657-4.99783-7 · Cited by 1
Upstream Therapy in the Treatment of Atrial Fibrillation
Băicuş, C. (2013) · Springer eBooks · doi:10.1007/978-1-4471-5475-4_4
It Takes the Right Medications to Prevent a Million Heart Attacks and Strokes
DiNicolantonio, J. J., Fuchs, F. D., & O’Keefe, J. H. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.11.2846
Antiarrhythmic therapy in patients with atrial fibrillation
Wysocka, A., Karaś-Głodek, M., & Wysokiński, A. P. (2015) · Postępy Nauk Medycznych
Grupo de Trabajo para el manejo de la hipertensión arterial de la Sociedad Europea de Hipertensión (ESH) y la Sociedad Europea de Cardiología (ESC)
Mancia, G., & Fagard, R. H. (2016)
New Antiarrhythmic Drugs and New Concepts for Old Drugs
Kirchhof, P. F. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2856-5.00112-6
OBSOLETE: Clinical Trials for Atrial Fibrillation - What do we know?
Wilton, S. B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.99783-6
Arrhythmias in Cardiomyopathy
Roukoz, H., Adkisson, W. O., Akdemir, B., Krishnan, B., Sakaguchi, S., & Benditt, D. G. (2017) · Springer eBooks · doi:10.1007/978-3-319-44577-9_19
Reconsideration of the Role of the Up-Stream Therapy in Atrial Fibrillation
Niwano, S. (2014) · Japanese Journal of Electrocardiology · doi:10.5105/jse.33.466
Innovations in Antiarrhythmic Drug Therapy
Kirchhof, P. F., & Fabritz, L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-44733-1.00113-9
The PREVER Study
Fuchs, S. C. P. C., & Fuchs, F. D. (2018) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-319-75310-2_36
Mechanisms of Antifibrillatory Agents for Atrial Fibrillation
Frommeyer, G., & Eckardt, L. (2019) · doi:10.1002/9781119152637.ch45
Antiarrhythmic Properties of Non-Antiarrhythmic Drugs in Atrial Fibrillation: Upstream Therapy
Scridon, A., & Martínez‐Rubio, A. (2020) · Springer eBooks · doi:10.1007/978-3-030-34893-9_7
Elevated chymase-dependent angiotensin II-forming activity in circulating mononuclear leukocytes was observed in the patient of atrial fibrillation
Okamura, K., Okuda, T., Takamiya, Y., Shirai, K., & Urata, H. (2020) · Heart and Vessels · doi:10.1007/s00380-020-01582-4
Effect Modification of Interventions. Bridging the Gap Between Clinical Studies and the Individual Patient
Schmidt, A. F. (2014) · Utrecht University Repository (Utrecht University)
Circulation Editors’ Picks
Editors, T. (2013) · Circulation · doi:10.1161/circulationaha.113.005495
Clinical Trials for Atrial Fibrillation—What Do We Know?
Kerr, N. P., Chew, D. S., & Wilton, S. B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15734-9.00023-6
Class I Antiarrhythmic Drugs: Na+ Channel Blockers
Shenasa, M., & Soleimanieh, M. (2024) · Springer eBooks · doi:10.1007/978-3-031-74046-6_3
Non-antiarrhythmic Drugs with Antiarrhythmic Properties
Scridon, A., Ivănescu, A. C., & Halațiu, V.-B. (2024) · Springer eBooks · doi:10.1007/978-3-031-74046-6_8
Additional file 1 of Impact of renin–angiotensin–aldosterone-system inhibitor drugs on mortality in patients with atrial fibrillation and hypertension
Xu, W., Yang, Y.-M., Zhu, J., Wu, S., Wang, J., Zhang, H., & 邵兴慧 (2022) · Figshare · doi:10.6084/m9.figshare.19498305
The Spectrum of Atrial Cardiomyopathy: Early Changes, Diagnostic Challenges, and Clinical Implications
Borizanova, A. (2026) · Cardiology and cardiovascular medicine. · doi:10.5772/intechopen.1013255
Strategies for preventing and reversing atrial cardiomyopathy: current evidence, therapeutic targets, and future directions. A European Journal of Heart Failure expert consensus statement
Zakeri, R., Camilli, M., D’Elia, E., Hulot, J., Iacoviello, M., Sisti, N., Țica, O., Tokmakova, M. P., den Eynde, J. V., Weerts, J., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag268
Impact of altered ventricular function on atrial cardiomyopathy: a discordant phenomenon
Goette, A. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag254
Experimental studies on new therapeutic approaches in atrial fibrillation
Linz, D. (2013) · doi:10.26481/dis.20131114dl

Authors: Goette, A., Schön, N., Kirchhof, P., Breithardt, G., Fetsch, T., Häusler, K. G., Klein, H. U., Steinbeck, G., Wegscheider, K., & Meinertz, T.
Affiliations: University Hospital Münster (DE)
ORCID: Goette, Andreas
Kirchhof, Paulus
Klein, Helmut U.
Steinbeck, Gerhard
Wegscheider, Karl
Venue: Circulation Arrhythmia and Electrophysiology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2012-02
Volume: 5
Issue: 1
Pages: 43-51
ISSN: 1941-3084 (ISSN-L)
1941-3149
DOI: 10.1161/circep.111.965178
OpenAlex: W2149897387
Semantic Scholar: 8bd7095a22f776dcc11d6318b6bf8f43f7fcc8f0
Cited by: 187
References: 34
Citations by year: 2026: 5 · 2025: 7 · 2024: 12 · 2023: 6 · 2022: 9 · 2021: 10 · 2020: 9 · 2019: 8 · 2018: 8 · 2017: 11 · 2016: 17 · 2015: 16 · 2014: 23 · 2013: 26 · 2012: 11
FWCI: 13.97
Type: journal article
Language: en
Open access: closed
Locations: Circulation Arrhythmia and Electrophysiology (publishedVersion)
PubMed (publishedVersion)
University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Arrhythmias and Treatments
Keywords: paroxysmal atrial fibrillation, angiotensin receptor blockers, olmesartan medoxomil, atrial fibrillation burden, atrial fibrillation recurrence, amiodarone, quality of life, structural heart disease, antiarrhythmic drugs, hospitalization, persistent atrial fibrillation, secondary prevention
MeSH terms: Atrial Fibrillation, Dose-Response Relationship, Drug, Double-Blind Method, Electrocardiography, Female, Follow-Up Studies, Germany, Humans, Imidazoles, Male, Middle Aged, Prospective Studies, Tachycardia, Paroxysmal, Tetrazoles, Time Factors, Incidence, Treatment Outcome, Angiotensin II Type 1 Receptor Blockers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) Trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks